International Journal of Preventive Medicine (Int J Prev Med)2008-7802942018041019051905ENDepartment of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, IsfahanIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, IsfahanDepartment of Epidemiology and Biostatistics, Isfahan Endocrine and Metabolism Research Center, School of Public Health, Isfahan University of Medical Sciences, IsfahanDepartment of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan20180410<p><span class="fontstyle0"><strong>Background</strong>: </span><span class="fontstyle2">Stroke as a devastating condition is one of the major causes of death worldwide. It is accountable for long time disability with high personal and social cost in adults. There are several risk factors for stroke such as diabetes and hypertension. Alpha‑lipoic acid (ALA) as an antioxidant can be a risk modifer in these patients. We designed this trial to scrutinize the possible effects of ALA consumption on some cardiovascular risk factors in patients experienced stroke. </span></p><p><strong></strong><span class="fontstyle0"><strong>Methods</strong>: </span><span class="fontstyle2">In this randomized, double‑blind, placebo‑controlled clinical trial, 67 patients experienced stroke were randomly allocated into two groups (taking a 600 mg ALA supplement or placebo daily for 12 weeks).<br />Fasting blood sugar (FBS), fasting insulin and systolic (SBP), and diastolic blood pressure (DBP) were measured before and after intervention in this study. Statistical analyses were performed using SPSS version 16 (SPSS Inc., Chicago, IL, USA) software. </span></p><p><span class="fontstyle0"><strong>Results</strong>: </span><span class="fontstyle2">Primary features were similar in the intervention and placebo groups (</span><span class="fontstyle3">P </span><span class="fontstyle2">&gt; 0.05). After the intervention period, SBP (</span><span class="fontstyle3">P </span><span class="fontstyle2">&lt; 0.001), DBP (</span><span class="fontstyle3">P </span><span class="fontstyle2">&lt; 0.001) and FBS (</span><span class="fontstyle3">P </span><span class="fontstyle2">&lt; 0.001) reduced in ALA group compared with placebo group, signifcantly. No signifcant change was seen in insulin level (</span><span class="fontstyle3">P </span><span class="fontstyle2">= 0.82). </span></p><p><span class="fontstyle0"><strong>Conclusions</strong>: </span><span class="fontstyle2">Results of this trial indicated that 12 weeks supplementation with 600 mg ALA has benefcial effects on SBP, DBP, and FBS but has no effect on insulin level.<br /></span></p><p><span class="fontstyle0" style="color: #00652e;"><strong>Keywords</strong>: </span><span class="fontstyle3">Blood glucose, blood pressure, insulin, thioctic acid</span> </p>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/1905http://ijpm.mui.ac.ir/index.php/ijpm/article/download/1905/717717730